Skip to Main content Skip to Navigation
Journal articles

Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA ‐positive myeloid neoplasm with eosinophilia: Data from 151 patients

Julien Rohmer 1, 2 Amélie Couteau‐chardon 1, 3 Julie Trichereau 1, 2 Kewin Panel 1, 2 Cyrielle Gesquiere 1 Raouf Ben Abdelali 4 Audrey Bidet 5 Jean‐sébastien Bladé 6 Jean‐michel Cayuela 7 Pascale Cony‐makhoul 1, 8 Vincent Cottin 9, 10 Eric Delabesse 11 Mikaël Ebbo 1, 12 Olivier Fain 13 Pascale Flandrin 14 Lionel Galicier 13 Catherine Godon 15 Nathalie Grardel 16 Aurélien Guffroy 1, 17 Mohamed Hamidou 1, 15 Mathilde Hunault 18 Etienne Lengline 7 Faustine Lhomme 19 Ludovic Lhermitte 20 Irène Machelart 1, 5 Laurent Mauvieux 21, 22 Catherine Mohr 23 Marie‐joelle Mozicconacci 24 Dina Naguib 25 Franck Nicolini 26 Jérôme Rey 24 Philippe Rousselot 27 Suzanne Tavitian 11 Louis Terriou 1, 28 Guillaume Lefèvre 1, 28 Claude Preudhomme 16 Jean‐emmanuel Kahn 1 Matthieu Groh 29, 30
18 CRCINA-ÉQUIPE 7 - Innate Immunity and Immunotherapy
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Abstract : FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia (F/P+ MN-eo) is a rare disease: robust epidemiological data are lacking and reported issues are scarce, of low sample-size and limited follow-up. Imatinib mesylate (IM) is highly efficient but no predictive factor of relapse after discontinuation has yet been identified. One hundred and fifty-one patients with F/P+ MN-eo (143 males; mean age at diagnosis 49 years; mean annual incidence: 0.18 case per million population) were included in this retrospective nationwide study involving all French laboratories who perform the search of F/P fusion gene (study period: 2003-2019). The main organs involved included the spleen (44%), skin (32%), lungs (30%), heart (19%) and central nervous system (9%). Serum vitamin B12 and tryptase levels were elevated in 74/79 (94%) and 45/57 (79%) patients, respectively, and none of the 31 patients initially treated with corticosteroids achieved complete hematologic remission. All 148 (98%) IM-treated patients achieved complete hematologic and molecular (when tested, n = 84) responses. Forty-six patients eventually discontinued IM, among whom 20 (57%) relapsed. In multivariate analysis, time to IM initiation (continuous HR: 1,01 [0.99-1,03]; P = .05) and duration of IM treatment (continuous HR: 0,97 [0,95-0,99]; P = .004) were independent factors of relapse after discontinuation of IM. After a mean follow-up of 80 (56) months, the 1, 5- and 10-year overall survival rates in IM-treated patients were 99%, 95% and 84% respectively. In F/P+ MN-eo, prompt initiation of IM and longer treatment durations may prevent relapses after discontinuation of IM.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03496695
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, December 20, 2021 - 2:54:36 PM
Last modification on : Tuesday, January 4, 2022 - 5:58:17 AM

Identifiers

Citation

Julien Rohmer, Amélie Couteau‐chardon, Julie Trichereau, Kewin Panel, Cyrielle Gesquiere, et al.. Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA ‐positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, Wiley, 2020, 95 (11), pp.1314-1323. ⟨10.1002/ajh.25945⟩. ⟨inserm-03496695⟩

Share

Metrics

Les métriques sont temporairement indisponibles